Inspire Pharmaceuticals, Inc.
(Public, NASDAQ:ISPH) Watch this stockFind more results for
ISPH
Advertisement
Events
Dec 2, 2009
Piper Jaffray Healthcare Conference
- 10:00AM EST -
Nov 5, 2009
Q3 2009 Earnings Conference Call -
Nov 5, 2009
Q3 2009 Earnings Release
Sep 22, 2009
UBS Global Life Sciences Conference -
Sep 16, 2009
BioCentury `NewsMakers in the Biotech Industry` Clear Route Investment Conference -
Sep 15, 2009
Morgan Stanley Global Healthcare Conference -
|
More events from AOL Finance »
|
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | -33.75% | -73.20% |
| Operating margin | -31.52% | -70.44% |
| EBITD margin | - | -66.08% |
| Return on average assets | -25.23% | -35.02% |
| Return on average equity | -49.23% | -75.84% |
| Employees | 250 | - |
Address
4222 Emperor Boulevard Suite 200
Durham, NC 27703
United States - Map
+1-919-9419777 (Phone)
+1-919-9419797 (Fax)
Durham, NC 27703
United States - Map
+1-919-9419777 (Phone)
+1-919-9419797 (Fax)
Website links
Company website:
http://www.inspirepharm.com/
http://www.inspirepharm.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Inspire Pharmaceuticals, Inc. discussed on blogs
Ranking 1500+ Small Cap Stocks by Year-to-Date Performance ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- 14 hours ago
Ranking Healthcare Stocks by Upside Potential - NASD100.com ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- Nov 19, 2009
Inspire Pharmaceuticals, Inc. discussions
View all discussions »Description
Inspire Pharmaceuticals, Inc. (Inspire) biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The Company’s portfolio of products and product candidates include Elestat, Restasis, AzaSite, Prolacria and Denufosol tetrasodium. The advanced compounds in its clinical pipeline are Prolacria for dry eye and denufosol tetrasodium for cystic fibrosis, which are both in Phase III development and AzaSite for blepharitis, which is beginning Phase II development.
Officers and directors
| Kenneth B. Lee Jr. | Chairman of the Board | |
| Christy L. Shaffer Ph.D. | President, Chief Executive Officer, Director | |
| Thomas R. Staab II | Chief Financial Officer, Treasurer | |
| Benjamin R. Yerxa Ph.D. | Executive Vice President and Chief, Research and Development | |
| Joseph K. Schachle | Executive Vice President, Chief - Commercial Operations | |
| Romulus Kim Brazzell Ph.D. | Executive Vice President and Head of Ophthalmology Business | |
| Joseph M. Spagnardi | Senior Vice President, General Counsel, Secretary | |
| Kip A. Frey | Director | |
| Richard S. Kent M.D. | Director | |
| Alan F. Holmer | Director |